


Supplementary Table I. Incidence rates of adverse events during the first 1 year of etanercept treatment.

	Standard-dose group (n=34)	Low-dose group (n=100)	<i>p</i> -value
Any adverse events	64.7 (40.6-98.0)	80. (63.4-99.6)	0.369
Uveitis	8.7 (1.0-31.4)	11.0 (5.5-19.7)	0.383
Infection	17.7 (6.5-38.4)	28.0 (18.6-40.5)	0.282
Injection site reaction	11.8 (3.2-30.1)	13.0 (6.9-22.2)	0.860
Headache	0 (0.0-16.4)	4.0 (1.1-10.2)	0.777
Gastroenteritis	5.9 (0.7-21.2)	5.0 (1.6-11.7)	0.848
Skin rash	8.8 (1.8-25.8)	5.0 (1.6-11.7)	0.450
Other*	11.7 (3.2-30.1)	14.0 (7.7-23.5)	0.755

Incidence rate (95% confidence interval) is expressed per 100 person-years.

*Including fatigue, tingling sense in extremity, and leukopenia

**Supplementary Fig. 1.** Balance of baseline characteristics before and after the propensity-score matching.